Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2

Objectives Determine the impact of 24-week risankizumab (RZB) versus placebo (PBO) on patient-reported outcomes (PROs) in patients with psoriatic arthritis (PsA) and inadequate response to one or two biologics (Bio-IR) and/or ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR...

Full description

Bibliographic Details
Main Authors: Kurt de Vlam, Alan Kivitz, Andrew J K Ostor, Zailong Wang, Ahmed M Soliman, Ann Eldred, Kim A Papp, Byron Padilla
Format: Article
Language:English
Published: BMJ Publishing Group 2022-11-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/8/2/e002286.full

Internet

https://rmdopen.bmj.com/content/8/2/e002286.full

Similar Items